<n-docbody><doc bill="Y"><content.metadata.block><cmd.identifiers><cmd.cites><cmd.second.line.cite><bop/><bos/>Multidistrict Lit Man § 5:53<eos/><eop/></cmd.second.line.cite></cmd.cites></cmd.identifiers></content.metadata.block><prop.block><prop.head toc-guid=""><bop/><bos/><headtext>Multidistrict Litigation Manual</headtext><eos/><eop/></prop.head><content.metadata.block><cmd.dates><cmd.currency.default iso.d="20190501"><bop/><bos/>May 2019 Update<eos/><eop/></cmd.currency.default></cmd.dates></content.metadata.block><author.line><bop/><bos/><author>David F. Herr[<footnote.reference refid="If4b7ee716b3e11e99b03e53d6dd36aa2">a0</footnote.reference>]</author><eos/><eop/></author.line><prop.head toc-guid="I97b7f560933b11da99e2b07024dacc26"><bop/><bos/><label.name>Part</label.name><label.designator>I.</label.designator><headtext>Handling Cases Before the Judicial Panel on Multidistrict Litigation</headtext><eos/><eop/></prop.head><prop.head toc-guid="Id8e3eb20933b11da99e2b07024dacc26"><bop/><bos/><label.name>Chapter</label.name><label.designator>5.</label.designator><headtext>Factors in Deciding Whether Transfer Is Appropriate</headtext><eos/><eop/></prop.head></prop.block><message.block><include.copyright n-include_collection="w_wlnv_msg" n-include_guid="I1DA35ED81DD211B281BAD200220BDFCA">Copyright (c) 2017 Thomson/RIA All rights reserved.</include.copyright></message.block><section><section.front><doc.title toc-guid="I94f3274ee1e311da9c26e67ca3b71335"><head parent="doc.title"><bop/><bos/><label.name>§ </label.name><label.designator>5:53.</label.designator><headtext>Arguments rejected by the Panel—Alternatives to transfer</headtext><eos/><eop/></head></doc.title></section.front><section.body><para><bop/><bos/><paratext>Parties frequently urge the Panel not to order transfer under § 1407 for the reason that there are alternatives that make transfer unnecessary. <eos/><bos/>These arguments are occasionally successful, but they most often are rejected by the Panel.[<eos/><bos/><footnote.reference refid="If4b7ee726b3e11e99b03e53d6dd36aa2">1</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>Probably the most frequently advanced alternative to transfer is the voluntary cooperation and coordination of the litigation among the parties. <eos/><bos/>This argument has generally not been successful. <eos/><bos/>In one case the Panel stated:</paratext><display.quote><para><paratext><begin.quote ID="QT_0001"/>Though voluntary cooperation among the parties as a means of avoiding duplicative discovery is commendable, placing these actions under the control of a single judge will ensure that duplicative discovery on the complex factual questions will be prevented and have the salutary effect of eliminating the possibility of conflicting pretrial rulings.<eos/><bos/><end.quote refid="QT_0001"/>[<footnote.reference refid="If4b815816b3e11e99b03e53d6dd36aa2">2</footnote.reference>]</paratext></para></display.quote><paratext>The Panel has, however, encouraged such voluntary cooperation and informal coordination in cases it determines are not appropriate for transfer.[<eos/><bos/><footnote.reference refid="If4b815826b3e11e99b03e53d6dd36aa2">3</footnote.reference>] The Panel has also suggested that it would not have ordered transfer if the parties had agreed on a discovery program and was ordering transfer, in part, because of the parties&apos; failure to do so.[<eos/><bos/><footnote.reference refid="If4b83c906b3e11e99b03e53d6dd36aa2">4</footnote.reference>] The decisions are thus not crystal-clear on what role this factor plays. <eos/><bos/>The biggest problem with this argument is, of course, that the cooperation of the parties may be ephemeral. <eos/><bos/>If the parties are, in fact, resolving their pretrial disputes without the necessity of court involvement, then transfer should have little impact on the process.<eos/></paratext><eop/></para><para><bop/><bos/><paratext>The Panel has frequently invoked “alternatives to transfer” as a explanation for not ordering transfer, but it has done so primarily when only a few cases are pending.[<eos/><bos/><footnote.reference refid="If4b83c916b3e11e99b03e53d6dd36aa2">5</footnote.reference>] Where the number of cases is large, viable alternatives to transfer are not likely to exist.[<eos/><bos/><footnote.reference refid="If4b83c926b3e11e99b03e53d6dd36aa2">6</footnote.reference>] The Panel has also noted that the fact that the parties in numerous cases were represented by the same counsel militated in favor of finding that “alternatives to transfer” exist.[<eos/><bos/><footnote.reference refid="If4b863a06b3e11e99b03e53d6dd36aa2">7</footnote.reference>] The Panel has, however, found alternatives to transfer even in actions involving many parties.[<eos/><bos/><footnote.reference refid="If4b863a16b3e11e99b03e53d6dd36aa2">8</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>The Panel has also rejected arguments that transfer is unnecessary because the courts in which the actions are pending have consolidated them for coordinated or consolidated pre-trial proceedings before a single judge.[<eos/><bos/><footnote.reference refid="If4b863a26b3e11e99b03e53d6dd36aa2">9</footnote.reference>] The cases considered by the Panel involve intracircuit coordination allowed under the Judicial Code.[<eos/><bos/><footnote.reference refid="If4b863a36b3e11e99b03e53d6dd36aa2">10</footnote.reference>] The Panel has again found that transfer is appropriate for reasons related to the possible need for transfer if the in-place alternative ceased functioning as intended and because transfer would not undermine the process if it was working.<eos/></paratext><eop/></para></section.body></section><author.footnotes><footnote ID="If4b7ee716b3e11e99b03e53d6dd36aa2"><label.designator>a0</label.designator><footnote.body><para><bop/><bos/><paratext>Maslon Edelman Borman &amp; Brand, LLP, Minneapolis, Minnesota.<eos/></paratext><eop/></para></footnote.body></footnote></author.footnotes><footnote.block><footnote ID="If4b7ee726b3e11e99b03e53d6dd36aa2"><label.designator>1</label.designator><footnote.body><para><bop/><bos/><paratext>The Panel&apos;s decisions relying on alternatives to transfer as a reason for denying transfer—whether argued by the parties or not—are discussed in <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs5:33" w-pub-number="185218" ID="If4b815806b3e11e99b03e53d6dd36aa2">§ 5:33</cite.query>, above.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4b815816b3e11e99b03e53d6dd36aa2"><label.designator>2</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914055" w-serial-number="1977106312" w-seq-number="00001" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1034" ID="I849544316b3e11e99f73e2698c313519">In re General Tire &amp; Rubber Co. Securities Litigation, 429 F. Supp. 1032, 1034 (J.P.M.L. 1977)</cite.query>. <eos/><bos/><ital>See also</ital> <cite.query w-src-number="0304914055" w-serial-number="2027545007" w-seq-number="00002" w-ref-type="RP" w-pub-number="0004637" ID="I849544336b3e11e99f73e2698c313519">In re Royal Alliance Associates, Inc., Securities Litigation, 856 F. Supp. 2d 1339 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2016825439" w-seq-number="00003" w-ref-type="RP" w-pub-number="0004637" ID="I849544356b3e11e99f73e2698c313519">In re Zurn Pex Plumbing Products Liability Litigation, 572 F. Supp. 2d 1380 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2016316633" w-seq-number="00004" w-ref-type="RP" w-pub-number="0004637" ID="I849544376b3e11e99f73e2698c313519">In re BP Products North America, Inc., Antitrust Litigation (No. II), 560 F. Supp. 2d 1377 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2015730641" w-seq-number="00005" w-ref-type="RP" w-pub-number="0004637" ID="I849544396b3e11e99f73e2698c313519">In re Virgin Mobile Initial Public Offering (IPO) Securities Litigation, 542 F. Supp. 2d 1372 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2015395207" w-seq-number="00006" w-ref-type="RP" w-pub-number="0004637" ID="I8495443b6b3e11e99f73e2698c313519">In re Gadolinium Contrast Dyes Products Liability Litigation, 536 F. Supp. 2d 1380 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2015333504" w-seq-number="00007" w-ref-type="RP" w-pub-number="0004637" ID="I8495443d6b3e11e99f73e2698c313519">In re Aurora Dairy Corp. Organic Milk Marketing and Sales Practices Litigation, 536 F. Supp. 2d 1369 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2009440493" w-seq-number="00008" w-ref-type="RP" w-pub-number="0004637" ID="I8495443f6b3e11e99f73e2698c313519">In re H &amp; R Block Mortg. Corp. Prescreening Litigation, 435 F. Supp. 2d 1347 (J.P.M.L. 2006)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2006265216" w-seq-number="00009" w-ref-type="RP" w-pub-number="0004637" ID="I849544416b3e11e99f73e2698c313519"><ital>In re Pharmastem Therapeutics, Inc., Patent Litigation</ital>, 360 F. Supp. 2d 1362 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2003639171" w-seq-number="00010" w-ref-type="RP" w-pub-number="0004637" ID="I849544436b3e11e99f73e2698c313519">In re Mosaid Technologies Inc., Patent Litigation, 283 F. Supp. 2d 1359 (J.P.M.L. 2003)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2003324064" w-seq-number="00011" w-ref-type="RP" w-pub-number="0004637" ID="I849544456b3e11e99f73e2698c313519">In re Gator Corp. Software Trademark &amp; Copyright Litigation, 259 F. Supp. 2d 1378 (J.P.M.L. 2003)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="1986162810" w-seq-number="00012" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="189" ID="I849544476b3e11e99f73e2698c313519">In re Dow Chemical Co. Sarabond Products Liability Litigation, 650 F. Supp. 187, 189 (J.P.M.L. 1986)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4b815826b3e11e99b03e53d6dd36aa2"><label.designator>3</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914055" w-serial-number="1978104221" w-seq-number="00013" w-ref-type="RP" w-pub-number="0000345" ID="I8496a3c16b3e11e99f73e2698c313519">In re Raymond Lee Organization, Inc. Securities Litigation, 446 F. Supp. 1266 (J.P.M.L. 1978)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="1978104116" w-seq-number="00014" w-ref-type="RP" w-pub-number="0000345" ID="I8496a3c36b3e11e99f73e2698c313519">In re Eli Lilly &amp; Co. (Cephalexin Monohydrate) Patent Litigation, 446 F. Supp. 242 (J.P.M.L. 1978)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="1978104118" w-seq-number="00015" w-ref-type="RP" w-pub-number="0000345" ID="I8496a3c56b3e11e99f73e2698c313519">In re Allen Compound Bow Patent Litigation, 446 F. Supp. 248 (J.P.M.L. 1978)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="1978104033" w-seq-number="00016" w-ref-type="RP" w-pub-number="0000345" ID="I8496a3c76b3e11e99f73e2698c313519">In re Wyeth Patent Infringement Litigation, 445 F. Supp. 992 (J.P.M.L. 1978)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="1977127072" w-seq-number="00017" w-ref-type="RP" w-pub-number="0000345" ID="I8496a3c96b3e11e99f73e2698c313519">In re Texas Instruments Inc. Employment Practices Litigation, 441 F. Supp. 928 (J.P.M.L. 1977)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="1977127071" w-seq-number="00018" w-ref-type="RP" w-pub-number="0000345" ID="I8496a3cb6b3e11e99f73e2698c313519">In re Southern Railway Employment Practices Litigation, 441 F. Supp. 926 (J.P.M.L. 1977)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4b83c906b3e11e99b03e53d6dd36aa2"><label.designator>4</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914055" w-serial-number="1972104194" w-seq-number="00019" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1339" ID="I84978e216b3e11e99f73e2698c313519">In re Kauffman Mut. Fund Actions, 337 F. Supp. 1337, 1339 (J.P.M.L. 1972)</cite.query>. <eos/><bos/><ital>See also</ital> <cite.query w-src-number="0304914055" w-serial-number="2038641650" w-seq-number="00020" w-ref-type="RP" w-pub-number="0007903" ID="I84978e236b3e11e99f73e2698c313519">In re Genentech Herceptin (Trastuzumab) Marketing and Sales Practices Litigation, 178 F. Supp. 3d 1374 (J.P.M.L. 2016)</cite.query> (Panel concludes that contentious relationship of counsel made voluntary cooperation an unlikely alternative to centralization).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4b83c916b3e11e99b03e53d6dd36aa2"><label.designator>5</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914055" w-serial-number="2016771288" w-seq-number="00021" w-ref-type="RP" w-pub-number="0004637" ID="I8499b1016b3e11e99f73e2698c313519">In re Arthur J. Gallagher Risk Management Services, Inc., Litigation, 571 F. Supp. 2d 1370 (J.P.M.L. 2008)</cite.query> (3 actions in 3 districts); <cite.query w-src-number="0304914055" w-serial-number="2015950562" w-seq-number="00022" w-ref-type="RP" w-pub-number="0004637" ID="I8499b1036b3e11e99f73e2698c313519">In re Medicare Fee Schedule Locality Litigation, 560 F. Supp. 2d 1344 (J.P.M.L. 2008)</cite.query> (2 actions in 2 districts); <cite.query w-src-number="0304914055" w-serial-number="2014535276" w-seq-number="00023" w-ref-type="RP" w-pub-number="0004637" ID="I8499b1056b3e11e99f73e2698c313519">In re Best Buy Co., Inc., Restocking Fee Sales Practices Litigation, 528 F. Supp. 2d 1364 (J.P.M.L. 2007)</cite.query> (2 actions in 2 districts); <cite.query w-src-number="0304914055" w-serial-number="2014519291" w-seq-number="00024" w-ref-type="RP" w-pub-number="0004637" ID="I8499b1076b3e11e99f73e2698c313519">In re Circuit City Stores, Inc., Restocking Fee Sales Practices Litigation, 528 F. Supp. 2d 1363 (J.P.M.L. 2007)</cite.query> (3 actions in 3 districts); <cite.query w-src-number="0304914055" w-serial-number="2009404757" w-seq-number="00025" w-ref-type="RP" w-pub-number="0004637" ID="I8499b1096b3e11e99f73e2698c313519">In re Edward D. Jones &amp; Co., Overtime Pay Litigation, 442 F. Supp. 2d 1370 (J.P.M.L. 2006)</cite.query> (3 actions in 3 districts); <cite.query w-src-number="0304914055" w-serial-number="2009440495" w-seq-number="00026" w-ref-type="RP" w-pub-number="0004637" ID="I8499b10b6b3e11e99f73e2698c313519">In re Bank of America Fiduciary Accounts Litigation, 435 F. Supp. 2d 1349 (J.P.M.L. 2006)</cite.query> (2 actions in 2 districts); <cite.query w-src-number="0304914055" w-serial-number="2004144168" w-seq-number="00027" w-ref-type="RP" w-pub-number="0004637" ID="I8499b10d6b3e11e99f73e2698c313519">In re Highway Accident in Buffalo County, Nebraska, 305 F. Supp. 2d 1359 (J.P.M.L. 2004)</cite.query> (3 actions in 2 districts); <cite.query w-src-number="0304914055" w-serial-number="2003554102" w-seq-number="00028" w-ref-type="RP" w-pub-number="0004637" ID="I8499b10f6b3e11e99f73e2698c313519">In re Equicredit Corp. Mortg. Lending Practices Litigation, 276 F. Supp. 2d 1381 (J.P.M.L. 2003)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2002528275" w-seq-number="00029" w-ref-type="RP" w-pub-number="0004637" ID="I8499b1116b3e11e99f73e2698c313519">In re DaimlerChrysler Corp. Seat Belt Buckle Products Liability Lit., 217 F. Supp. 2d 1376 (J.P.M.L. 2002)</cite.query> (2 actions); <cite.query w-src-number="0304914055" w-serial-number="2002392125" w-seq-number="00030" w-ref-type="RP" w-pub-number="0004637" ID="I8499b1136b3e11e99f73e2698c313519">In re W.E. Hall Co., Inc., Patent Litigation, 206 F. Supp. 2d 1367 (J.P.M.L. 2002)</cite.query> (2 actions); <cite.query w-src-number="0304914055" w-serial-number="2002392004" w-seq-number="00031" w-ref-type="RP" w-pub-number="0004637" ID="I8499b1156b3e11e99f73e2698c313519">In re Pharmacy Ben. Plan Administrators Pricing Litigation, 206 F. Supp. 2d 1362 (J.P.M.L. 2002)</cite.query> (2 actions); <cite.query w-src-number="0304914055" w-serial-number="2002259201" w-seq-number="00032" w-ref-type="RP" w-pub-number="0004637" ID="I8499b1176b3e11e99f73e2698c313519">In re Lawrence Moore/International Brotherhood of Electrical Workers Litigation, 198 F. Supp. 2d 1382 (J.P.M.L. 2002)</cite.query> (2 actions); <cite.query w-src-number="0304914055" w-serial-number="2002259199" w-seq-number="00033" w-ref-type="RP" w-pub-number="0004637" ID="I8499b1196b3e11e99f73e2698c313519">In re Plasma Display Panels Patent Litigation, 196 F. Supp. 2d 1378 (J.P.M.L. 2002)</cite.query> (2 actions); <cite.query w-src-number="0304914055" w-serial-number="2002141977" w-seq-number="00034" w-ref-type="RP" w-pub-number="0004637" ID="I8499b11b6b3e11e99f73e2698c313519">In re Chromated Copper Arsenate (CCA) Treated Wood Products Liability Litigation, 188 F. Supp. 2d 1380 (J.P.M.L. 2002)</cite.query> (2 actions); <cite.query w-src-number="0304914055" w-serial-number="2002141974" w-seq-number="00035" w-ref-type="RP" w-pub-number="0004637" ID="I8499b11d6b3e11e99f73e2698c313519">In re Monochloroacetic Acid (MCAA) Antitrust Litigation, 187 F. Supp. 2d 1381 (J.P.M.L. 2002)</cite.query> (2 actions); <cite.query w-src-number="0304914055" w-serial-number="1978104116" w-seq-number="00036" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="244" ID="I8499b11f6b3e11e99f73e2698c313519">In re Eli Lilly &amp; Co. (Cephalexin Monohydrate) Patent Litigation, 446 F. Supp. 242, 244 (J.P.M.L. 1978)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4b83c926b3e11e99b03e53d6dd36aa2"><label.designator>6</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914055" w-serial-number="2038992581" w-seq-number="00037" w-ref-type="RP" w-pub-number="0007903" ID="I849ae9816b3e11e99f73e2698c313519">In re Air Crash over the Southern Indian Ocean, on March 8, 2014, 190 F. Supp. 3d 1358 (U.S.J.P.M.L. 2016)</cite.query> (alternatives not likely to be workable for a 40-case docket with more filings likely).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4b863a06b3e11e99b03e53d6dd36aa2"><label.designator>7</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914055" w-serial-number="2027872468" w-seq-number="00038" w-ref-type="RP" w-pub-number="0004637" ID="I849b85c16b3e11e99f73e2698c313519">In re Ocala Funding, LLC, Commercial Litigation, 867 F. Supp. 2d 1332 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2027545191" w-seq-number="00039" w-ref-type="RP" w-pub-number="0004637" ID="I849b85c36b3e11e99f73e2698c313519">In re Northeast Contaminated Beef Products Liability Litigation, 856 F. Supp. 2d 1354 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2026698620" w-seq-number="00040" w-ref-type="RP" w-pub-number="0004637" ID="I849b85c56b3e11e99f73e2698c313519">In re Plavix Products Liability Litigation, 829 F. Supp. 2d 1378 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2027911970" w-seq-number="00041" w-ref-type="RP" w-pub-number="0004637" ID="I849b85c76b3e11e99f73e2698c313519">In re Bulk Mailing to County Jail Inmates in the State of Washington, 867 F. Supp. 2d 1339 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2026300776" w-seq-number="00042" w-ref-type="RP" w-pub-number="0004637" ID="I849b85c96b3e11e99f73e2698c313519">In re Ronald Beecher Estate Litigation, 816 F. Supp. 2d 1379 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2026300773" w-seq-number="00043" w-ref-type="RP" w-pub-number="0004637" ID="I849b85cb6b3e11e99f73e2698c313519">In re Global Distribution Systems (GDS) Antitrust Litigation, 816 F. Supp. 2d 1378 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2007565825" w-seq-number="00044" w-ref-type="RP" w-pub-number="0004637" ID="I849b85cd6b3e11e99f73e2698c313519">In re Oxycontin Products Liability Litigation (No. II), 395 F. Supp. 2d 1358 (J.P.M.L. 2005)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4b863a16b3e11e99b03e53d6dd36aa2"><label.designator>8</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914055" w-serial-number="2027545191" w-seq-number="00045" w-ref-type="RP" w-pub-number="0004637" ID="I849cbe416b3e11e99f73e2698c313519">In re Northeast Contaminated Beef Products Liability Litigation, 856 F. Supp. 2d 1354 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2026698620" w-seq-number="00046" w-ref-type="RP" w-pub-number="0004637" ID="I849cbe436b3e11e99f73e2698c313519">In re Plavix Products Liability Litigation, 829 F. Supp. 2d 1378 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2026300776" w-seq-number="00047" w-ref-type="RP" w-pub-number="0004637" ID="I849cbe456b3e11e99f73e2698c313519">In re Ronald Beecher Estate Litigation, 816 F. Supp. 2d 1379 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2026300773" w-seq-number="00048" w-ref-type="RP" w-pub-number="0004637" ID="I849cbe476b3e11e99f73e2698c313519">In re Global Distribution Systems (GDS) Antitrust Litigation, 816 F. Supp. 2d 1378 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="2016771286" w-seq-number="00049" w-ref-type="RP" w-pub-number="0004637" ID="I849cbe496b3e11e99f73e2698c313519">In re Aegon USA, Inc., Supplemental Cancer Ins. Litigation, 571 F. Supp. 2d 1369 (J.P.M.L. 2008)</cite.query> (7 actions in 5 districts, but factual issues not particularly complex); <cite.query w-src-number="0304914055" w-serial-number="2016771274" w-seq-number="00050" w-ref-type="RP" w-pub-number="0004637" ID="I849cbe4b6b3e11e99f73e2698c313519">In re Shoulder Pain Pump-Chondrolysis Products Liability Litigation, 571 F. Supp. 2d 1367 (J.P.M.L. 2008)</cite.query> (13 actions in 8 districts, but numerous factual differences in actions); <cite.query w-src-number="0304914055" w-serial-number="2016316628" w-seq-number="00051" w-ref-type="RP" w-pub-number="0004637" ID="I849cbe4d6b3e11e99f73e2698c313519">In re Title Ins. Real Estate Settlement Procedures Act (RESPA) &amp; Antitrust Litigation, 560 F. Supp. 2d 1374 (J.P.M.L. 2008)</cite.query> (25 actions, but different regulatory schemes in each state militate in favor of finding alternatives to transfer exist).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4b863a26b3e11e99b03e53d6dd36aa2"><label.designator>9</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914055" w-serial-number="1978122919" w-seq-number="00052" w-ref-type="RP" w-pub-number="0000345" ID="I849e1dd16b3e11e99f73e2698c313519">In re Women&apos;s Clothing Antitrust Litigation, 455 F. Supp. 1388 (J.P.M.L. 1978)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="1974107382" w-seq-number="00053" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="502" ID="I849e1dd36b3e11e99f73e2698c313519">In re Air Crash Disaster at Pago Pago, Am. Samoa, on January 30, 1974, 383 F. Supp. 501, 502 (J.P.M.L. 1974)</cite.query>; <cite.query w-src-number="0304914055" w-serial-number="1974106798" w-seq-number="00054" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="800" ID="I849e1dd56b3e11e99f73e2698c313519">In re Gas Vent Pipe Antitrust Litigation, 380 F. Supp. 799, 800 (J.P.M.L. 1974)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4b863a36b3e11e99b03e53d6dd36aa2"><label.designator>10</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914055" w-seq-number="00055" w-ref-type="LQ" w-normalized-cite="28USCAS292" w-pub-number="1000546" ID="I849e93006b3e11e99f73e2698c313519">28 U.S.C.A. § 292(b)</cite.query>. <eos/><bos/>This statute is set forth in full in <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs3:19" w-pub-number="185218" ID="If4b88ab06b3e11e99b03e53d6dd36aa2">§ 3:19</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote></footnote.block><content.metadata.block><cmd.royalty><cmd.copyright><bop/><bos/>Westlaw. © 2019 Thomson Reuters.  <eos/><bos/>No Claim to Orig. U.S. Govt. <eos/><bos/>Works.<eos/><eop/></cmd.copyright></cmd.royalty><cmd.identifiers><cmd.cites><cmd.first.line.cite><bop/><bos/>MDLITMAN § 5:53<eos/><eop/></cmd.first.line.cite></cmd.cites></cmd.identifiers></content.metadata.block></doc></n-docbody>
